Memantine Hydrochloride Tablet
Product Images NDC 50090-7356

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 50090-7356). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907356)

Memantine hydrochloride 10 mg oral tablets packaging label from A-S Medication Solutions. The label includes the NDC 50090-7356-1 and states the package contains 60 tablets in a 10 mg strength. Storage instructions are to keep the product at 60 to 77 degrees Fahrenheit.*

FDA Label Image

Memantinetabs-figure6 (Memantinetabs Figure6)

A cumulative percentage of patients chart showing ADCS-ADL change from baseline. The chart compares two groups: Placebo/Donepezil (black squares) and Memantine Hydrochloride Tablets/Donepezil (open circles), illustrating their response distributions over a range of change values.*

FDA Label Image

Memantinetabscamberlogo (Memantinetabscamberlogo)

FDA Label Image

Memantinetabsfigure1 (Memantinetabsfigure1)

A line graph comparing mean change from baseline in ADCS-ADL scores over 28 weeks of treatment between placebo and memantine hydrochloride tablets. The x-axis shows weeks of treatment (0, 4, 12, 28), and the y-axis shows mean change scores with error bars. Placebo group shows decline; memantine group shows stable or slight improvement. Clinical improvement and decline are noted on the graph.*

FDA Label Image

Memantinetabsfigure2 (Memantinetabsfigure2)

A cumulative percentage of patients chart comparing the effects of memantine hydrochloride tablets and placebo on ADCS-ADL change from baseline. The graph plots cumulative percentage of patients on the vertical axis against ADCS-ADL change from baseline on the horizontal axis, showing two curves representing placebo and memantine hydrochloride tablets.*

FDA Label Image

Memantinetabsfigure3 (Memantinetabsfigure3)

A line graph comparing the mean change from baseline in SIB score over 28 weeks of treatment between memantine hydrochloride tablets and placebo. The graph shows clinical improvement and decline thresholds, with memantine hydrochloride maintaining stable scores near baseline, while placebo scores decline over time, indicating clinical decline. Error bars representing SEM are included for each time point.*

FDA Label Image

Memantinetabsfigure4 (Memantinetabsfigure4)

A line graph showing the cumulative percentage of patients over weeks of treatment. The x-axis represents weeks of treatment from 0 to 28, with an additional scale for SIB change from baseline. Two data series are plotted: one for Placebo and one for Memantine Hydrochloride Tablets, illustrating changes in patient response over time.*

FDA Label Image

Memantinetabsfigure5 (Memantinetabsfigure5)

A line graph depicting the mean change from baseline in ADCS-ADL scores over 24 weeks of treatment. It compares two groups: one treated with placebo/donepezil and the other with memantine hydrochloride tablets/donepezil. The vertical axis shows mean change with error bars, and the horizontal axis indicates weeks of treatment. The graph notes 'Clinical Improvement' at the zero change level and 'Clinical Decline' below.*

FDA Label Image

Memantinetabsfigure7 (Memantinetabsfigure7)

A line graph showing mean change from baseline in SIB score over 24 weeks of treatment comparing Memantine Hydrochloride Tablets/Donepezil (open circles) with Placebo/Donepezil (filled squares). The y-axis ranges from -4 to 4 indicating clinical decline to clinical improvement, with Memantine Hydrochloride Tablets/Donepezil showing greater improvement over time compared to placebo.*

FDA Label Image

Memantinetabsfigure8 (Memantinetabsfigure8)

A cumulative percentage of patients chart showing SIB (Severe Impairment Battery) change from baseline with two groups: Placebo/Donepezil and Memantine Hydrochloride Tablets/Donepezil. The x-axis represents SIB change from baseline, ranging from approximately +20 to -30, while the y-axis shows the cumulative percentage of patients from 0 to 100%. The graph compares cognitive changes in patients between the two treatments.*

FDA Label Image

Memantinetabsstructure (Memantinetabsstructure)

Chemical structure of memantine hydrochloride showing the arrangement of its atoms including an amine group, methyl groups, and the hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.